While the large proportion of our genome that does not instruct our cells to form proteins has been harder to study than protein-coding genes, it has been shown to have vital physiological functions. Scientists at Karolinska Institutet have now developed new high-precision tools able to identify what these noncoding sequences do. The study, which is published in the journal Nature Genetics, may eventually contribute to the development of new, targeted drugs.
Only a small proportion of our genome comprises genes that instruct the cells to make specific proteins; the majority are so-called noncoding DNA, sometimes called “junk DNA” given that their function has been largely unknown. However, recent research has shown that some of these sequences can give rise to RNA which affects vital cellular processes. It transpires that most of the genetic changes linked to different diseases lie in these very noncoding parts of patients’ DNA.
May become attractive drug candidates
“This has come as a great surprise and we now need to understand in detail how these genetic changes affect different diseases in order to eventually be able to develop more accurate drugs,” says the study’s first author , researcher at the Karolinska Institutet. “Generally speaking we don’t know that much about this interaction, but we believe that noncoding RNA will one day be a source of attractive drug candidates. It’s therefore extremely important that we speed up the characterisation of these RNA molecules.”
For this study, the researchers combined single-cell sequencing with mathematical calculations to show that it is possible in this way to identify the function of noncoding RNA, something that has proved very difficult before. Using these tools, they were then able to identify an entirely new mechanism for how the RNA molecules regulate the activity of protein-coding genes in their vicinity.
“After many years of development, single-cell sequencing has now reached a stage where we can isolate individual cells and study regulating mechanisms with high precision,” says principal investigator , professor at the Department of Cell and Molecular Biology, Karolinska Institutet. “This is multidisciplinary research that we believe will contribute significantly to our basic understanding of cell biology and that, in the long run, can give us new insights into how cellular function can be influenced through the agency of small drug substances.”
Study many genes in parallel
The group has so far used the method to study the function of a handful of noncoding RNA molecules, but there are thousands of similar molecules waiting to be characterised. They now plan to do similar work on RNA molecules with a possible role in the development of disease, such as cancer.
“We’ll be applying larger-scale methods to study hundreds to thousands of similar genes in parallel, thus greatly advancing our understanding of these interesting RNA molecules,” says Dr Johnsson.
The study was financed by the Swedish Research Council, the Knut and Alice Wallenberg Foundation, the Göran Gustafsson Foundation and the Vallee Foundation. There are no reported conflicts of interest.
Publication
. Per Johnsson, Christoph Ziegenhain, Leonard Hartmanis, Gert-Jan Hendriks, Michael Hagemann-Jensen, Björn Reinius and Rickard Sandberg. Nature Genetics, online 3 March 2022, doi: 10.1038/s41588-022-01014-1.
